Hikma Pharmaceuticals PLC announced the appointments of Laura Balan and Victoria Hull as independent non-executive directors with effect from 1 October and 1 November 2022 respectively. In line with its plans for the future composition of the company board, Victoria will be appointed Senior Independent Director and assume the role of Chair of the Nomination and Governance Committee during the course of 2023. The effective date for these changes will be confirmed in the 2022 Annual Report.

About Laura Balan: Laura worked for 17 years at The Capital Group Companies, the US investment manager with $2.6 trillion under management, where she recently retired from her role as partner. Covering the European healthcare and pharmaceutical sectors while at Capital, Laura gained a deep understanding of international business, the pharmaceutical industry globally, key sector trends and dynamics. Prior to her time at Capital, she held associate and analyst roles at The Goldman Sachs Group Inc, focused on European healthcare and global investment research.

Laura in an investment professional and CFA Charterholder, she holds an BA(Hons) in International Business from the Bucharest Academy of Economic Studies. About Victoria Hull: An experienced non-executive director, Victoria is currently serving Non-Executive Directorships and Remuneration Committee Chair positions for IQE PLC, Alphawave IP Group PLC and Network International Holdings PLC. Victoria was also the Senior Independent Director for Ultra Electronics Holdings PLC, until their acquisition by a private equity firm in August 2022.

During her executive career, Victoria wasChief Legal Officer and Executive Directorat Invensys Plc, now Schneider Electric, from 2001 to 2014.Prior to this, she held various roles at Telewest Communications PLC from 1994 to 2001, including Executive Director and Chief Legal Officer & Company Secretary. Victoria is a solicitor and began her career at Clifford Chance LLP.